Greenwich LifeSciences (GLSI) Stock Analysis

What Greenwich LifeSciences does

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Key metrics

ETFs linked to GLSI

Broad-market and Healthcare sector ETFs an investor holding Greenwich LifeSciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GLSI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Greenwich LifeSciences?

Greenwich LifeSciences trades under the ticker GLSI on NASDAQ.

Which exchange is GLSI listed on?

GLSI is listed on NASDAQ.

What sector does Greenwich LifeSciences operate in?

Greenwich LifeSciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GLSI in a portfolio?

PortView shows GLSI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.